SCHEMBL24257827

SCHEMBL24257827

COC(=O)c1nc(C)cc(CCOCc2ccccc2)c1O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RNASEH1 O60930 1/20 0.47
▸ HPGD P15428 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ERCC1 P07992 1/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ ERCC4 Q92889 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ AR P10275 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ TLR8 Q9NR97 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452343 1.00 RNASEH1 (0.47) RNASEH1HPGDLMNAERCC1FEN1
SCHEMBL24257810 0.89 RNASEH1 (0.40) RNASEH1HPGDALDH1A1GAAKDM4E
SCHEMBL30454412 0.89 RNASEH1 (0.40) RNASEH1HPGDALDH1A1GAAKDM4E
Glycine SCHEMBL30546853 0.85 TDP1 (0.39) LMNAALDH1A1GAAKDM4ETDP1
SCHEMBL24257456 0.84 EGLN1 (0.48) —
Glycine SCHEMBL29248942 0.84 RNASEH1 (0.37) RNASEH1HPGDALDH1A1GAAKDM4E
SCHEMBL24257784 0.81 PPID (0.43) HPGDLMNAALDH1A1GAAKDM4E
Formic Acid SCHEMBL30454433 0.81 EGLN1 (0.45) —
SCHEMBL30452335 0.81 PPID (0.43) HPGDLMNAALDH1A1GAAKDM4E
SCHEMBL23044131 0.76 KDM4E (0.48) HPGDLMNAALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 — — US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 — — CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 RNASEH1 2628/4885HPGD 109/4885LMNA 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback